AMH and breast cancer: Rosendahl et al. [12] reported significantly lower AMH levels in patients who received alkylating agents, whereas in the study of Dezellus et al. [3] 231 of 250 patients with breast cancer (92.4%) who received CTX-positive regimens had CRA at the end of chemotherapy.